New adulterants in opioid supply

Medetomidine, a veterinary sedative showing up in illicit fentanyl, is changing how overdoses look and how long people stay sedated. (cdc.gov) The Centers for Disease Control and Prevention issued a national Health Alert Network advisory on April 2, 2026, warning that medetomidine is being detected in drug seizures, paraphernalia samples, clinical testing, and wastewater across the United States. The agency said the drug can cause profound sedation, slow heart rate, low blood pressure, and a severe withdrawal syndrome after regular exposure. (cdc.gov) Medetomidine was first found in the drug supply with illegally made fentanyl in 2021, according to the Centers for Disease Control and Prevention. National Forensic Laboratory Information System reports rose from 247 in 2023 to 2,616 in 2024 and then to 8,233 in 2025. (cdc.gov) The Centers for Disease Control and Prevention said fentanyl remains involved in most medetomidine overdoses, so naloxone should still be given to restore breathing. The problem is that naloxone does not treat medetomidine itself, and clinicians are being told to consider the drug when a patient stays deeply sedated after opioid reversal medication. (cdc.gov) The spread is concentrated in the Northeast and Midwest, where the Centers for Disease Control and Prevention said 52% and 31% of 2025 forensic reports came from those regions. In provisional testing from July through December 2025, 10 of 20 sentinel sites found medetomidine in more than one-third of opioid-positive samples. (cdc.gov) Federal officials are framing medetomidine as the next shift in an adulterant market already shaped by xylazine. The White House Office of National Drug Control Policy said on April 6 that medetomidine detections had risen sharply and called attention to street names including “rhino tranq,” “mede,” and “dex.” (whitehouse.gov) Drug Enforcement Administration analysts said in an October 2024 street report that medetomidine and dexmedetomidine could become supplements to or replacements for xylazine in illicit opioids. The report said the substances first emerged in U.S. laboratory submissions in 2021 and have been found in fake pills, white powders, gel capsules, marijuana, and drug-packaging residue. (dea.gov) Xylazine remains a parallel policy fight. The White House designated fentanyl adulterated or associated with xylazine as an emerging drug threat on April 12, 2023, and Senator Ashley Moody said on April 22, 2026, that she is cosponsoring the Combating Illicit Xylazine Act, which would regulate xylazine while preserving veterinary access. (whitehouse.gov, saveoursociety.org) The National Institute on Drug Abuse says xylazine, like medetomidine, is a veterinary tranquilizer that people often take unknowingly when it is mixed into fentanyl. The institute says naloxone does not reverse xylazine’s effects either, although it should still be used in a suspected opioid overdose. (nida.nih.gov) Pharmacy Times put a sharper label on the medetomidine trend in an October 13, 2025 report, calling it “the demon” in the illicit fentanyl supply. Its authors wrote that pharmacists and other clinicians need to recognize the drug early because there is no Food and Drug Administration-approved reversal agent for medetomidine exposure. (pharmacytimes.com) The immediate advice from federal agencies has not changed: treat slowed or stopped breathing as an opioid overdose, give naloxone, call 911, and expect that some patients may stay sedated or develop withdrawal that needs emergency care. The drug in the bag may still be fentanyl, but the drug supply now carries another sedative that responders are being told to look for. (cdc.gov, cdc.gov)